Gluco quant glucose hk

Plasma glucose and triacylglycerol (mM) concentrations were measured in duplicate using Gluco-quant Glucose/HK and TG GPO-PAP kits (Roche Diagnostics (Mannheim, Germany)), respectively, on the COBAS Bio automated analysis system (Roche Diagnostics Australia Pty Ltd (Castle Hill, Australia)). Plasma insulin concentrations (pM) were measured by DRG Ultrasensitive Mouse Insulin ELISA (DRG Instruments (Marburg, Germany)) as per manufacturer’s instructions.

Blood samples for pharmacodynamic assessments (PG and insulin) were collected on Days −1, 1, and 16 at −0.5, −0.25, 0, 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 4.5 (prior to lunch), 5, 5.5, 6, 6.5, 7, 8, 9, 10.5 (prior to dinner), 11, 12, 12.5, 13, 14, 16, 19, 22, and 24 hours. Morning FPG was obtained on Day 2 and within 30 minutes prior to dosing on Days 3 to 15 and prior to breakfast on Days 17 to 20.
Urine samples for the assessment of UGE were collected at intervals of 0 to 2, 2 to 4.5, 4.5 to 7, 7 to 10.5, 10.5 to 13, and 13 to 24 hours on Days −1, 1, and 16. On all other days, urine was collected over the interval of 0 to 24 hours.
Plasma glucose and insulin and urine glucose analyses were performed by MLM Medizinische Laboratorien, Marienhof, Germany. Plasma and urine glucose were analyzed by the hexokinase/glucose-6-phosphate dehydrogenase method using Gluco-quant Glucose/HK (Roche Diagnostics GmbH, Mannheim, Germany). Plasma insulin was analyzed by the electrochemiluminescence immunoassay (ECLIA) method (Roche Diagnostics Ltd., Rotkreuz, Switzerland).
As a result of inappropriate bioanalytical data manipulation by a single chemist, the pharmacokinetics data for canagliflozin from the current study were not considered reliable and are not included in this manuscript. Pharmacokinetics data with canagliflozin in patients with T2DM have been reported previously [21] (link).

Variants in GCK were identified using sequencing. Samples were collected from a population-based cohort of 6,058 individuals both with and without diabetes [50 (link)], 2,930 patients with newly-diagnosed diabetes [51 (link)], patients diagnosed with GCK-MODY [53 (link)] and from a population of 1,146 Danish children [52 (link)]. Individuals were included if they carried one missense GCK variant according to transcript NM_000162 and if a measure of fasting plasma glucose was available. Measures of fasting plasma glucose were examined using a glucose oxidase method (Granutest; Merck, Darmstadt, Germany) in the population based cohort and in samples from patients with known GCK-MODY [50 (link), 53 (link)], an enzymatic hexokinase method (Gluco-quant Glucose/HK, Roche Diagnostics) in newly diagnosed diabetes patients [51 (link)], and using a Dimension Vista® 1500 Analyzer (Siemens, Erlangen, Germany) in children [52 (link)]. Samples were excluded if fasting plasma glucose level exceeded 9 mM.